Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia

(2017) Xinyu Qin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa

(2017) Adnan Alatoom et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae

(2017) Zhen Shen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

(2016) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)

(2016) Wright W. Nichols et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates

(2016) Deanna J. Buehrle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014

(2016) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)

(2016) Boudewijn L. M. de Jonge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

(2016) Florian M. Wagenlehner et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

(2016) Lesley J. Scott   DRUGS

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

(2016) Henri Merdjan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA)

(2016) Massimo Sartelli et al.   World Journal of Emergency Surgery

Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria

(2016) Andre Arizpe et al.   Current Infectious Disease Reports

Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

(2015) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam

(2015) Jean-Marie Pagès et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

(2015) Yoav Golan   BMC INFECTIOUS DISEASES

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies

(2015) Henri Merdjan et al.   CLINICAL DRUG INVESTIGATION

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

(2015) Antoine Tarral et al.   CLINICAL THERAPEUTICS

Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases

(2015) Krisztina M. Papp-Wallace et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

(2015) Raymond Testa et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control

(2015) T. Tängdén et al.   JOURNAL OF INTERNAL MEDICINE

The emerging threat of multidrug-resistant Gram-negative bacteria in urology

(2015) Hosam M. Zowawi et al.   Nature Reviews Urology

In VivoEfficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates

(2014) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

(2014) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of Ceftazidime-Avibactam Combination inIn VitroCheckerboard Assays

(2014) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa

(2014) Marisa L. Winkler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

(2013) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

(2012) R. Cantón et al.   CLINICAL MICROBIOLOGY AND INFECTION

Characterization of  -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)

(2012) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

(2012) A. E. Muller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases

(2011) P. R. S. Lagacé-Wiens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae

(2010) Andrea Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Current Challenges in Antimicrobial Chemotherapy

(2010) Carine Bebrone et al.   DRUGS

Infections with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae

(2010) Johann D.D. Pitout   DRUGS